Evidence map›Paper›PMID 41428153›Full record

ArticleEJNMMI radiopharmacy and chemistry2025

Preclinical characterization of 3p-C-DEPA

Jessica Pougoue Ketchemen, Stephen Ahenkorah, Emmanuel Nwangele, Siphelele Siphesihle Pearl Malaza, Maarten Ooms, Thomas Cardinaels, Simon Leekens, Frederik Cleeren, Humphrey Fonge

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jessica Pougoue Ketchemen *Faculté de Pharmacie, Université Laval, Québec, QC, Canada.ORCID http://orcid.org/0000-0002-4574-8720
Stephen Ahenkorah *Nuclear Medical Applications Institute, Belgian Nuclear Research Center (SCK CEN), Mol, Belgium.ORCID http://orcid.org/0000-0002-3632-829X
Emmanuel NwangeleFaculté de Pharmacie, Université Laval, Québec, QC, Canada.
Siphelele Siphesihle Pearl MalazaRadiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, University of Leuven (KU Leuven), Leuven, Belgium.ORCID http://orcid.org/0000-0002-7533-1491
Maarten OomsNuclear Medical Applications Institute, Belgian Nuclear Research Center (SCK CEN), Mol, Belgium.ORCID http://orcid.org/0000-0002-7489-1630
Thomas CardinaelsDepartment of Chemistry, University of Leuven (KU Leuven), Leuven, Belgium.ORCID http://orcid.org/0000-0002-2695-1002
Simon LeekensRadiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, University of Leuven (KU Leuven), Leuven, Belgium.
Frederik CleerenRadiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, University of Leuven (KU Leuven), Leuven, Belgium. frederik.cleeren@kuleuven.be.
Humphrey FongeFaculté de Pharmacie, Université Laval, Québec, QC, Canada. humphrey.fonge@crchudequebec.ulaval.ca.ORCID http://orcid.org/0000-0001-9388-6872

Funding

Institute of Cancer Research 408132Institute of Cancer Research 437660Onderzoeksraad, KU Leuven Onderzoeksraad, KU Leuven
6 · The paper itself

Abstract

backgroundActinium-225 (

resultsThe BFCs 3p-C-DEPA-

conclusions3p-C-DEPA

Indexed as

3p-C-DEPA3p-C-DEPA-TFP-PEG₄Actinium-225Bifunctional chelatorsTargeted alpha therapyTrastuzumab

Identifiers

PMID41428153
PMCPMC12722590

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.